You participated in our first townhall of 2025 in Q1, at which we got together as ONE Team. On 13 March we get a better overview on all functions, platforms and expert groups among peers in a new format to drive DSO initiatives and digital transformation. POAP dropped for Bayer DT&IT Pharma Design by stefankai with Canva POAP Terms & Conditions: https://bayer.com/poap Bayer IT POAP Collection: https://collections.poap.xyz/bayer-it/

You were invited to our Q4/2024 Townhall, where we explored our future organization based on what has been agreed upon until then. Updates from our Leadership Team included insights from the PH Strategy Summit, which did initiate discussions on our financials and the strategic mid- and long-term outcomes for Pharma. Additionally, we reflected on the results of the Ownership Pulse (formerly known as Employee Voice), discussed further considerations, and allocated time for a Q&A session. This token serves as appreciation for and proof of your participation. POAP dropped for Bayer DT&IT Pharma Design by stefankai with Canva POAP Terms & Conditions: https://bayer.com/poap Bayer IT POAP Collection: https://collections.poap.xyz/bayer-it/

Thank you for attending today's DT & IT Pharma Townhall! In today's meeting, we delved deeper into the successful launch of the Pharma Control Tower (go/PHCT), which serves as a central entry point for all your needs related to financial, operational stability, and governance for your applications, portfolios, and functions. Additionally, we shared some updates on the rollout of MyGenAssist at Pharma, highlighting our crucial role as key ambassadors. This past year has underscored the accelerated pace of innovation, with GenAI standing out as a prime example of the agility needed to proactively evolve our skill sets. Furthermore, we collectively reviewed our key priorities for 2024 and provided updates on our DSO learning journey. In summary: ///// PH Control Tower ///// Business priorities per department ///// MyGenAssist roll-out PH ///// DSO Champions update Bayer terms & conditions apply: https://www.bayer.com/en/poap-tc

For the participation on the CID EMEA LATAM Team Meeting 2024 in Barcelona, Spain

Dear CID expert, you have met all Team members today in valuable 90 min. to exchange on DSO & other topics of expertise with the chance to clarify open questions. We are ONE Team and have the same spirit like our peers in the Bayer 04 Leverkusen soccer team. Stay tuned & let's connect! ___ Image created by Stefankai with Midjourney AI and Canva Bayer POAP Term&Conditions: https://bayer.com/poap More info on business use of POAPS at https://go/poap Explore Bayer POAP Collection at https://collections.poap.xyz/bayer

Rare diseases are defined by their low prevalence in the population, leading to challenges in diagnosis, research, and treatment. Definitions vary; in the US, a disease is rare if it affects fewer than 1:1,500 individuals, Europe 1:2,000, Japan 1:2,500. There are some 7,000 rare diseases, impacting around 6-8% of the world at some point, some 300 million currently. They are incredibly diverse, ranging from genetic disorders to rare cancers, and can be chronic, progressive, debilitating, and often life-threatening. Some well-known rare diseases include cystic fibrosis, Duchenne muscular dystrophy, and Huntington's disease, each with their own unique symptoms, treatment challenges, and research needs. Rare diseases are closely related to orphan diseases, a term that originally referred to diseases neglected by drug developers due to the small market potential. However, the terms are now often used interchangeably. Legislation such as the Orphan Drug Act of 1983 in the U.S. has incentivized pharmaceutical companies to develop treatments for rare (orphan) diseases, offering benefits like tax credits and exclusive marketing rights. The rarity and diversity of these diseases pose significant hurdles for research and clinical trials, Raising awareness and support for those affected are crucial for research funding to develop diagnostics, treatments, and hopefully cures. https://en.wikipedia.org/wiki/Rare_disease Art+Text supported by ChatGPT